Treating acute neurotraumatic injuries

Acute traumatic injuries : absolute emergencies

30.000 new cases per year in USA+EU; no treatment; standard of care : decompressive surgery;
Victims are mostly: young males (traffic and sport accidents) + the elderly ones (falls).
Long-term handicaps include paraplegia and tetraplegia.

5-7 million new cases per year; no treatment; standard of care: none;
Victims are mostly : kids and males (sport, violence, traffic, wars, work accidents);
long-term disabilities include depression, memory deficits, higher prevalence of neurological Disorders (Parkinson, dementias).

3-5 million new cases per year; consists in sudden ischemia (blot clots, 80% cases) or hemorraghia ;
Most frequent in the elderly but fast growing in younger people;
Removal of blood clot is possible within the first 4h post-trauma (benefits to less than 20% patients)
In any case : neuronal loss is irreversible.

Act fast to limit secondary damages

Spinal Cord injuries, Traumatic Brain Injuries and Strokes, a cascade of damages

acute_traumatic_injury

EPICENTER
The initial trauma called the initial lesion, is focal and/or diffuse:
Compression
Contusion
Stretching
Distortion
Laceration
Hematoma
Hypoxia

WAVES OF DEATH
Leads to cascades of damages called secondary lesions that spread from initial lesion:Neuronal suffering and death

Our positioning : an emergency injection of MAP4343 to prevent secondary damages after the initial lesion.

MAP4343 promotes rapid and Impressive recovery after acute traumatic injuries

Studies supported by OSEO and by the US Army

In 3 different animal models of Spinal Cord Injuries, MAP4343:

In 3 different animal models of Traumatic Brain Injuries, MAP4343:

In the most widely used animal model of Stroke, MAP4343:

MAP4343 received the orphan drug status from EMA for treating Spinal Cord Injuries.
An emergency injection of MAP4343 will prevent secondary damages and help neurons to regenerate, while helping general rehabilitation and mood thanks of its safe antidepressive property.
Phase 2 Clinical trials are starting.

CHU Bicêtre, Batiment Pincus, 80 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France.